Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Menadione (MD), a vitamin K analog, has shown potential anticancer properties.
• Understanding its cytotoxicity spectrum and mechanisms is crucial for therapeutic development.

Purpose of the Study:

• To evaluate the cytotoxic effects of menadione (MD) across a panel of human cancer cell lines.
• To investigate the interactions between MD and established anticancer drugs.
• To explore the molecular mechanisms underlying MD's anticancer activity.

Main Methods:

• Cytotoxicity assays were performed on various human cancer cell lines, including multidrug-resistant and methotrexate-resistant lines.
• Drug-drug interaction studies were conducted in vitro.
• Incorporation of radiolabeled precursors (thymidine, uridine, amino acids) into DNA, RNA, and protein was measured.
• Intracellular adenosine triphosphate (ATP) levels were assessed.

Main Results:

• Menadione (MD) exhibited equipotent cytotoxicity against multidrug-resistant and parental leukemia cell lines.
• A methotrexate-resistant cervical carcinoma cell line showed sensitivity comparable to its parental line.
• MD inhibited DNA, RNA, and protein synthesis in cancer cells.
• Most interactions with other anticancer drugs were additive, with some synergistic and one antagonistic effect observed.
• No significant impact on total intracellular ATP pools was detected.

Conclusions:

• Menadione (MD) demonstrates broad-spectrum anticancer activity in vitro against diverse human cancer cell lines.
• MD's ability to inhibit macromolecular synthesis suggests a potential role in cancer therapy.
• Further investigation into the precise mechanisms of MD action in human cancer cells is warranted.